Moderna and life edit therapeutics enter strategic collaboration to accelerate the development of novel in vivo gene editing therapies

Collaboration to combine moderna's mrna platform with life edit's proprietary gene editing technologies, including base editing capabilities multi-target collaboration to advance potentially life-transformative or curative therapies for some of the most challenging genetic diseases life edit to receive upfront cash payment, research, and preclinical funding, and is eligible to receive milestone payments with tiered royalties on global net product sales cambridge, ma and durham, nc / accesswire / february 22, 2023 / moderna, inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines and life edit therapeutics inc., an elevatebio company focused on next-generation gene editing technologies and therapeutics, today announced a strategic research and development collaboration to discover and develop in vivo mrna gene editing therapies. the partnership will combine life edit's suite of proprietary gene editing technologies, including base editing, with moderna's mrna platform to advance in vivo gene editing therapies against a select set of therapeutic targets.
MRNA Ratings Summary
MRNA Quant Ranking